Healthcare · NIFTY 500

Alkem Laboratories Limited

NSEALKEM BSE539523 ISININE540L01014 SeriesEQ Listed on NSE · BSE

₹5,302.00 -146.00 (-2.68%) Updated 12 Nov, 6:16 pm IST

Open chart Back to screener

Price, daily close-6.48% in a year

Today

Open: ₹5,422.00
Prev close: ₹5,448.00
Day high: ₹5,422.00
Day low: ₹5,173.00
Volume: 10.00 L
Value traded: ₹526.22 Cr
Upper circuit: ₹5,480.00
Lower circuit: ₹5,161.00
52W high: ₹5,933.50
52W low: ₹4,811.00
1 month: +0.90%
6 months: -5.40%

52W low52W high

Ratios

Key numbers

Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.

Market cap₹63,385 Cr

P/E (TTM)29.38

P/B4.59

Book value / share₹1,156.01

EPS (TTM)₹180.44

ROE15.6%

Dividend yield1.00%

Dividend (12m)₹53.00 / share

Net margin (TTM)14.3%

Operating margin20.5%

Debt / equity0.12

Current ratio2.55

EV / EBITDA22.77

Sales growth (YoY qtr)+10.95%

Profit growth (YoY qtr)-21.72%

Sales CAGR 3Y+8.25%

Profit CAGR 3Y+32.74%

Shares11.96 Cr

Quarterly results

Results for each quarter

Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.

Revenue and net profit

3,440621

Sep 23

3,324595

Dec 23

2,936294

Mar 24

3,032545

Jun 24

3,415689

Sep 24

3,374626

Dec 24

3,144306

Mar 25

3,371664

Jun 25

4,001765

Sep 25

3,737636

Dec 25

3,603236

Mar 26

3,740520

Jun 26

Revenue · QoQ (vs last quarter)

—-3.4%-12%+3.3%+13%-1.2%-6.8%+7.2%+19%-6.6%-3.6%+3.8%

Revenue · YoY (vs a year ago)

————-0.7%+1.5%+7.1%+11%+17%+11%+15%+11%

Net profit · QoQ (vs last quarter)

—-4.1%-51%+86%+26%-9.1%-51%+117%+15%-17%-63%+120%

Net profit · YoY (vs a year ago)

————+11%+5.2%+4.2%+22%+11%+1.6%-23%-22%

RevenueNet profitLine = trend

51.90

Sep 23

49.76

Dec 23

24.55

Mar 24

45.60

Jun 24

57.60

Sep 24

52.34

Dec 24

25.57

Mar 25

55.56

Jun 25

63.99

Sep 25

53.19

Dec 25

19.77

Mar 26

43.49

Jun 26

EPS (₹) · YoY (vs a year ago)

————+11%+5.2%+4.2%+22%+11%+1.6%-23%-22%

EPS (₹)Line = trend

₹ Cr	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
Revenue	3,440	3,324	2,936	3,032	3,415	3,374	3,144	3,371	4,001	3,737	3,603	3,740
Other income	63.2	93.6	88.2	120	134	93.0	146	136	104	143	200	153
Total income	3,503	3,418	3,024	3,152	3,549	3,467	3,290	3,508	4,105	3,880	3,803	3,893
Raw material	825	839	799	837	902	924	777	827	906	938	895	910
Purchases	432	461	381	383	354	397	380	397	472	328	498	366
Employee cost	555	572	506	602	610	625	616	693	710	722	712	809
Other expenses	811	740	921	745	847	786	857	768	969	915	1,126	964
Total expenses	2,798	2,711	2,644	2,533	2,769	2,736	2,893	2,750	3,209	3,046	3,246	3,121
Operating profit	689	656	389	609	753	759	391	752	921	775	382	766
OPM %	20.0%	19.7%	13.3%	20.1%	22.0%	22.5%	12.4%	22.3%	23.0%	20.7%	10.6%	20.5%
Finance cost	30.3	25.5	26.9	29.1	28.1	36.0	28.4	29.8	35.0	42.1	53.9	46.6
Depreciation	73.9	69.6	83.4	80.5	78.9	85.3	112	87.7	93.6	95.0	106	100
Exceptional items	-57.7	-51.3	-12.5	—	—	—	—	12.9	—	-52.8	-135	—
Profit before tax	648	655	367	619	780	731	396	771	896	781	423	772
Tax	33.2	50.6	62.9	69.1	78.3	90.3	73.3	103	116	128	171	251
Net profit	615	604	304	550	702	641	322	668	779	653	251	521
Profit to shareholders	621	595	294	545	689	626	306	664	765	636	236	520
EPS (₹)	51.90	49.76	24.55	45.60	57.60	52.34	25.57	55.56	63.99	53.19	19.77	43.49

Profit & loss

Results for each year

8 financial years (April to March), consolidated, ₹ crore.

Sales, operating profit and net profit

6,4311,028631

FY18

7,3571,115761

FY19

8,3441,4731,127

FY20

10,6342,0381,646

FY22

11,5991,506984

FY23

12,6682,1241,796

FY24

12,9652,5122,165

FY25

14,7122,8302,302

FY26

Revenue · YoY (vs a year ago)

—+14%+13%—+9.1%+9.2%+2.3%+13%

Net profit · YoY (vs a year ago)

—+21%+48%—-40%+82%+21%+6.3%

RevenueOperating profitNet profitLine = trend

₹ Cr	FY18	FY19	FY20	FY22	FY23	FY24	FY25	FY26
Revenue	6,431	7,357	8,344	10,634	11,599	12,668	12,965	14,712
Other income	96.0	87.7	104	163	216	311	494	583
Total expenses	5,601	6,490	7,189	8,938	10,408	10,834	10,931	12,250
Employee cost	1,192	1,362	1,505	1,963	2,131	2,201	2,454	2,837
Operating profit	1,028	1,115	1,473	2,038	1,506	2,124	2,512	2,830
OPM %	16.0%	15.2%	17.7%	19.2%	13.0%	16.8%	19.4%	19.2%
Finance cost	55.3	54.6	65.1	52.4	107	112	122	161
Depreciation	143	193	253	304	310	299	357	382
Profit before tax	926	955	1,260	1,844	1,305	2,023	2,527	2,871
Tax	288	181	110	164	298	212	311	518
Tax rate %	31.1%	19.0%	8.8%	8.9%	22.8%	10.5%	12.3%	18.0%
Net profit	638	774	1,149	1,680	1,007	1,811	2,215	2,351
Profit to shareholders	631	761	1,127	1,646	984	1,796	2,165	2,302
Net margin %	9.8%	10.3%	13.5%	15.5%	8.5%	14.2%	16.7%	15.6%
EPS (₹)	52.77	63.61	94.26	137.63	82.31	150.19	181.11	192.51

Balance sheet

Assets and debt

At each year end (and the latest half year), ₹ crore.

Equity, debt and assets

9,0451,397274

Mar 23

10,3121,214455

Mar 24

11,9851,063304

Mar 25

13,8201,624248

Mar 26

Shareholders' equity · YoY (vs a year ago)

—+14%+16%+15%

Shareholders' equityBorrowingsCashLine = trend

₹ Cr	Mar 23	Mar 24	Mar 25	Mar 26
Shareholders' equity	9,045	10,312	11,985	13,820
Long-term borrowings	70.3	40.0	311	492
Short-term borrowings	1,326	1,174	752	1,131
Total borrowings	1,397	1,214	1,063	1,624
Current liabilities	3,707	3,995	3,959	4,783
Fixed assets (PPE)	2,065	2,161	2,064	2,695
Inventories	2,608	2,661	2,922	3,333
Trade receivables	2,132	2,253	2,466	2,979
Cash & equivalents	274	455	304	248
Current assets	8,606	10,412	10,811	12,211
Total assets	13,757	15,575	17,691	20,873
Debt / equity	0.15	0.12	0.09	0.12

Cash flow

Cash coming in and going out

For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.

Operating, investing and financing cash

1,111-1,435380

FY22

1,683113-1,761

FY23

1,948-1,009-1,145

FY24

1,913-1,299-811

FY25

1,963-1,667-503

FY26

Operations · YoY (vs a year ago)

—+51%+16%-1.8%+2.6%

OperationsInvestingFinancingLine = trend

₹ Cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	1,111	1,683	1,948	1,913	1,963
Cash from investing	-1,435	113	-1,009	-1,299	-1,667
Cash from financing	380	-1,761	-1,145	-811	-503
Spent on fixed assets	-339	-233	-259	-676	-617
Free cash flow	772	1,450	1,689	1,237	1,346
Net cash flow	55.5	34.5	-205	-197	-208

Shareholding

Who holds the shares

Promoter and public holding at each quarter end, as filed with NSE.

Holding over time

56.7%Sep 23

56.7%Dec 23

56.7%Mar 24

56.4%Jun 24

55.7%Sep 24

55.7%Dec 24

55.1%Mar 25

53.0%Jun 25

51.2%Sep 25

51.2%Dec 25

51.2%Mar 26

49.7%Jun 26

Promoter & groupPublic

Latest (30 Jun 2026)

49.7%promoter

Promoter & group: 49.70%
Public (FIIs, mutual funds, retail…): 50.30%
Promoter change, last quarter: -1.50 pts

Dividends & news

Latest dividends and announcements

Dividends & corporate actions

Dividend - Rs 10 Per ShareEx 07-Aug-2026
Interim Dividend - Rs 43 Per ShareEx 20-Feb-2026
Dividend - Rs 8 Per ShareEx 08-Aug-2025
Interim Dividend - Rs 37 Per ShareEx 14-Feb-2025
Dividend - Rs 5 Per ShareEx 09-Aug-2024
Interim Dividend - Rs 35 Per ShareEx 16-Feb-2024
Dividend - Rs 10 Per ShareEx 10-Aug-2023
Interim Dividend - Rs 15 Per Share & Special Dividend Rs 25 Per ShareEx 17-Feb-2023

Board meetings

ALKEM LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to inter-alia consider and approve the Unaudited F…12-Nov-2026
the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026.12-Nov-2026
ALKEM LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 14-Aug-2026 to inter-alia consider and approve the Unaudited F…14-Aug-2026
Notice of meeting of the Board of Directors of Alkem Laboratories Limited ( the Company )14-Aug-2026
the Yearly Audited Financial results of the Company for the period ended March 2026 and Dividend.28-May-2026

Filings with NSE

Trading Window12 Nov
Investor Presentation12 Nov
Appointment12 Nov
Outcome of Board Meeting12 Nov
General Updates8 Nov
Analysts/Institutional Investor Meet/Con. Call Updates4 Nov
Analysts/Institutional Investor Meet/Con. Call Updates4 Nov

Latest news

Alkem Laboratories trading window opens November 16 after Q2 resultsscanx.trade · 12 Nov, 2:19 pm ALKEM Outlook for the WeekEquitypandit · 8 Nov, 1:30 pm Earnings call transcript: Alkem Laboratories posts solid Q2 2027 sales, shares slip By Investing.comInvesting.com India · 12 Nov, 5:41 pm Alkem Laboratories Q2 profit falls 12% YoY to ₹675 crore, EBITDA grows 22%; board appoints new CFOUpstox · 12 Nov, 2:57 pm Alkem Labs Q2 Results: Revenue rises 14%, but profit and margins fall; shares drop 4%CNBC TV18 · 12 Nov, 2:12 pm Alkem Laboratories shares fall over 2% after CFO Nitin Agrawal resignsMoneycontrol.com · 24 Sep, 12:30 pm Alkem Labs up 6% on Q4 beat; early Tolvaptan launch, tax cut cheer StreetBusiness Standard · 29 May, 12:30 pm Five reasons behind Investec's upgrade of Alkem Labs, and why JPMorgan is cautiousCNBC TV18 · 17 Aug, 12:30 pm

About

About Alkem Laboratories Limited

Alkem Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Specialising in generics and speciality pharmaceuticals, Alkem manufactures and markets pharmaceutical generics, formulations and nutraceuticals across India and global markets.

From Wikipedia (CC BY-SA 4.0).

Company details

Company name: Alkem Laboratories Limited
NSE symbol: ALKEM
BSE scrip code: 539523
ISIN: INE540L01014
Listed on: NSE, BSE
Series: EQ (normal equity)
Listed on NSE since: 23 Dec 2015
Face value: ₹2 per share
Market lot: 1 share
Shares issued: 11.96 crore
Index: NIFTY 500
Sector (NSE): Healthcare
Industry: Pharmaceuticals: Major
Managing director / CEO: Sandeep Singh
Chair: Basudeo N. Singh
Headquarters: Mumbai
Registered address: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai – 400013, Maharashtra, India
Founded: 1973
Employees: 23,386
Financial year: April to March
Results basis: Consolidated
Website: alkemlabs.com

Peers

Other Healthcare stocks

Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

Alkem Laboratories Limited

Today

Ratios

Quarterly results

Revenue and net profit

Profit & loss

Sales, operating profit and net profit

Balance sheet

Equity, debt and assets

Cash flow

Operating, investing and financing cash

Shareholding

Holding over time

Latest (30 Jun 2026)

Dividends & news

Dividends & corporate actions

Board meetings

Filings with NSE

Latest news

About

Company details

Peers